Meristem Family Wealth’s Biogen BIIB Stock Holding History

Meristem Family Wealth’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,233	Closed	-$296K	–	349
2021 Q4	$296K	Buy	1,233 +13	+1%	+$3.34K	0.03%	301
2021 Q3	$345K	Buy	+1,220	New	+$400K	0.03%	284

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Meristem Family Wealth's BIIB Position: Q1 2022 in Review

Meristem Family Wealth sold out of Biogen (BIIB) in Q1 2022, closing a stake of 1,233 shares — an estimated $296K sold.

Meristem Family Wealth first reported a position in BIIB in Q3 2021 and held it in 2 quarters. The position peaked at $345K in Q3 2021. 952 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

Meristem Family Wealth reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
Meristem Family Wealth sold 1,233 Biogen shares in Q1 2022, an estimated $296K.
Meristem Family Wealth first reported a position in Biogen in Q3 2021 and held it in 2 quarters.
Meristem Family Wealth's Biogen position peaked at $345K in Q3 2021.
952 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on Meristem Family Wealth's 13F filing for Q1 2022, filed 11 May 2022.